Section 32

Endor Labs specializes in enhancing application security with a focus on managing open-source software dependencies. The company aids developers in integrating safe Open Source Software (OSS) to expedite development processes while minimizing time spent on security issues. Its Dependency Lifecycle Management Platform targets the vulnerabilities in software supply chain security caused by ungoverned use of open-source software within enterprises.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Sola Security is a cyber security company currently in Stealth mode.

Network Bio is a company that specializes in creating a clinical and molecular data library aimed at advancing precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, facilitating research by allowing scientists to identify patterns and correlations. This capability is essential for the development of new treatments and diagnostic tools, contributing to more personalized healthcare solutions. Through its innovative approach, Network Bio supports the research community in addressing significant health challenges.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

TollBit is a technology company that operates a content monetization platform. It enables AI bots and data scrapers to directly pay websites for licensing their content, thereby protecting the integrity of the content ecosystem. The platform monitors and blocks unauthorized AI bot traffic, manages licensing deals, and helps digital publishers strategize their content monetization.

Sunbird Bio is a diagnostics platform developer focused on advancing molecular diagnostics to deliver faster and more accurate results. Founded by Huilin Shao, the company specializes in detecting a wide array of diseases, including infectious diseases, neurodegenerative disorders, and cancer. By enabling early diagnosis, Sunbird Bio aims to enhance healthcare outcomes and support physicians in making informed decisions. The platform is designed to improve clarity and accessibility in diagnostic testing, thereby contributing to better patient care.

Basecamp Research is a pioneering company specializing in the mapping of biodiversity to facilitate the AI-driven design of biological systems. By utilizing BaseGraph™, an advanced AI design platform, the company refines and customizes novel proteins tailored to specific industrial, therapeutic, or diagnostic applications. This innovative approach leverages a high-resolution map of global genetic biodiversity, allowing Basecamp Research to comprehend the genetic, evolutionary, and environmental contexts of proteins. As a result, the company can create targeted proteins without resorting to costly and lengthy directed evolution processes. Composed of a diverse team of explorers, scientists, and policy experts, Basecamp Research is committed to understanding and preserving nature's diversity while delivering transformative solutions to pressing global challenges.

Nusano is a physics firm specializing in the production of radioisotopes, which are essential for diagnosing and treating cancer and various other medical conditions. The company has developed an advanced ion source and linear accelerator designed to overcome the limitations associated with traditional radioisotope manufacturing. By offering a diverse array of diagnostic and therapeutic radioisotopes produced without uranium, Nusano supports healthcare clients in the development of radiopharmaceuticals aimed at personalized cancer therapies. This innovative approach allows for the creation of these critical medical products at relatively lower costs, contributing to advancements in medical applications and improving patient outcomes.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Brightside Health, Inc. is a telemedicine platform based in San Francisco, California, focused on providing evidence-based mental health treatments for anxiety and depression. Established in 2017, the company offers a mobile application that facilitates personalized treatment experiences through video consultations, messaging, and ongoing support, including medication delivery. Brightside Health employs precision psychiatry and clinically proven therapeutic approaches to evaluate and monitor patients' mental health. Its platform provides tools and resources for lifestyle management, therapy referrals, and progress tracking, enabling individuals to access quality care and improve their well-being. The company was previously known as Good Measure, Inc. before rebranding in February 2018.

Ema offers a Universal AI employee designed to automate complex workflows and improve productivity within organizations. Utilizing the Generative Workflow Engine, Ema integrates seamlessly with enterprise applications, allowing users to delegate repetitive tasks efficiently. The platform combines multiple AI models to ensure accuracy and security, making it a valuable asset for various business functions such as customer support, HR, and finance.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

Puzzle Financial is a stealth mode SaaS startup focused on developing core accounting software designed to improve financial decision-making for startups. The platform aims to create a scalable foundation that supports fundraising, tax management, and real-time insights into overall business health. By transforming traditional accounting practices into a system of financial intelligence, Puzzle Financial enables startups to enhance their financial performance and gain greater trust and confidence in their financial operations.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Inceptive is a biotechnology company that specializes in designing RNA molecules through the integration of large-scale deep learning and high-throughput experimental methods. The company focuses on creating innovative biological software tools that facilitate the rational design of novel medicines and biotechnologies. By enabling the development of synthetic molecules for complex biological functions, Inceptive aims to advance healthcare and biotechnological solutions that were previously beyond reach, thus positioning itself at the forefront of medical and scientific innovation.

Endor Labs specializes in enhancing application security with a focus on managing open-source software dependencies. The company aids developers in integrating safe Open Source Software (OSS) to expedite development processes while minimizing time spent on security issues. Its Dependency Lifecycle Management Platform targets the vulnerabilities in software supply chain security caused by ungoverned use of open-source software within enterprises.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

AltPep Corp is a biomedical startup that specializes in diagnosing and treating amyloid diseases, which are known for their complexity and difficulty in management. The company has developed a proprietary peptide-based platform designed to diagnose and neutralize toxic precursors associated with these diseases. This innovative approach includes diagnostic, therapeutic, and anti-biofilm applications, particularly aimed at the early detection of toxic oligomers in Alzheimer's disease through a soluble oligomer binding assay. By focusing on early detection and effective treatment strategies, AltPep aims to enhance healthcare outcomes related to amyloid diseases, ultimately improving human health.

Delve Bio is a biotechnology company focused on delivering molecular insights for precision patient care. It specializes in the pathogen-agnostic and unbiased detection of neuro-infectious pathogens in cerebrospinal fluid (CSF) through a single test. This capability equips laboratories and clinicians with essential information for diagnosing both routine and rare infectious diseases, thereby enhancing patient care and treatment outcomes.

Function Oncology is a precision medicine company focused on transforming cancer treatment through its innovative CRISPR-powered personalized functional genomics platform. This platform enables the identification of therapeutic opportunities tailored to individual patients, allowing for a deeper understanding of cancer at a patient-specific level. By leveraging advanced genomic techniques, Function Oncology aims to develop targeted cancer therapies that address the unique characteristics of each patient's disease, ultimately advancing the future of cancer care.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

Forward Networks, founded in 2013 and based in Palo Alto, California, specializes in developing software for network verification and automation. The company offers open-source tools like Beacon and Mininet to manage data centers and wide-area networks, along with Forward Essentials, a web application that provides real-time network state access, helping engineers and operators swiftly identify and resolve network issues. Their core product is an innovative platform delivering network visibility, policy verification, and change modeling, designed to minimize costly outages by enabling users to visualize complex networks, debug problems quickly, verify policy correctness, and predict network behavior before implementing changes in legacy, SDN, or hybrid environments.

MedCrypt Inc. is a cybersecurity company specializing in the protection of medical devices. Founded in 2016 and based in Encinitas, California, MedCrypt provides data security solutions for a wide range of medical devices, including implantable devices like pacemakers and various surgical robots. The company's platform offers data security as a service to medical device original equipment manufacturers (OEMs), enabling them to implement essential security features quickly and efficiently. These features include user authentication, data encryption, and transaction monitoring to detect potential malicious behavior. By integrating security capabilities into medical devices with minimal code, MedCrypt allows engineers to focus on developing innovative clinical functionalities while ensuring the safety and integrity of device operations.

Neocis, Inc. is a Miami-based company that specializes in the development and manufacturing of robotic guidance systems for dental implant procedures. Founded in 2009, Neocis offers Yomi, a precision robotic instrument that aids in the placement of dental implants by integrating computer imagery from CT scans with the surgical planning process. This technology enhances the capabilities of dental surgeons, providing multi-sensory feedback to improve the accuracy and efficiency of procedures. Yomi is designed to facilitate a minimally invasive approach, allowing for quicker surgeries and faster patient recovery. The company’s focus is on collaborating with dental professionals to address surgical challenges and advance patient care through innovative robotics.

Stairwell, Inc. is a cybersecurity company that specializes in developing software-as-a-service (SaaS) solutions designed to enhance threat detection and response capabilities for organizations. Founded in 2019 and headquartered in Palo Alto, California, Stairwell offers an innovative platform that automates threat analysis by treating all files as suspicious and preserving them as evidence. This approach allows security teams to conduct comprehensive compromise assessments rapidly, delivering timely reports on potential threats and their impact on the organization. The company's technology leverages artificial intelligence and machine learning to provide actionable insights, enabling security professionals to effectively track threats and their variants across their environments. Recognized as one of the most innovative companies of 2023 by Fast Company, Stairwell aims to empower security teams with advanced tools that enhance their ability to respond to cybersecurity incidents efficiently.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Spectral, established in 2020 and headquartered in New Rochelle, New York, specializes in developing an AI-driven platform for creating and deploying sophisticated smart contracts. This platform facilitates the generation of complex smart contracts using natural language, expediting development time and minimizing errors.

Inworld AI is an AI framework powering massive consumer applications. Inworld is funded by VCs including Lightspeed, Stanford University, Kleiner Perkins, Founders Fund, Section 32, M12, Intel Capital, CRV, Bitkraft, and Meta, as well as a team of all-star angels including corporate executives, top VC funds' partners, scouts, and industry veterans.

Pomelo is a fintech-as-a-service platform focused on providing innovative payment solutions in Latin America. The company has developed a digital processing platform designed to enhance payment services by allowing businesses to create virtual accounts and issue prepaid and credit cards. This is achieved through compliant onboarding processes, which facilitate the customization required by fintech companies and embedded finance players for their specific programs. By redefining the possibilities in payment services, Pomelo aims to support the growth and efficiency of financial technology in the region.

BigHat Biosciences, Inc. is a biotechnology company based in San Carlos, California, founded in 2019. The company specializes in developing an automated platform that combines a wet laboratory with artificial intelligence and machine learning techniques for the production and characterization of antibodies. This innovative platform empowers drug developers to engineer antibodies and other therapeutic proteins with improved biophysical properties and complex functions. By leveraging AI-guided design capabilities, BigHat aims to create safer and more effective treatments for patients facing challenging diseases, thereby advancing the field of biotherapeutics.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Swadesh is a digital banking platform tailored for the Indian diaspora, facilitating a seamless financial experience for users managing their money in India from abroad. The company offers a range of services, including the ability to open bank accounts, invest, remit funds, and efficiently manage finances across borders. By focusing on the specific needs of Indian expatriates, Swadesh aims to simplify the complexities of banking and financial management, allowing customers to handle their financial affairs with ease and convenience.

Manifold Biotechnologies, Inc. is a biotechnology company that specializes in developing platforms for the pharmacological measurement of various therapeutic protein variants. By integrating DNA technologies with machine learning, the company aims to create protein drugs that address challenging diseases. Manifold Bio's innovative approach includes a protein barcoding platform designed to enable multiplexed quantitation of protein therapeutics, thereby generating extensive data that enhances the drug development process. Founded in 2019 and located in Allston, Massachusetts, the company is focused on advancing measurement-driven design in the field of protein therapeutics.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

MoMa Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2019. The company specializes in discovering precision medicines by targeting the molecular machines that are fundamental to human disease. Formerly known as ATPases NewCo, Inc., MoMa Therapeutics utilizes a unique platform that leverages the shared characteristics of ATPase enzymes, including their large-scale conformational changes and energy-driven mechanics. By integrating advances in structural biology and small-molecule drug discovery, MoMa Therapeutics aims to develop therapies targeting this previously challenging class of enzymes, thereby advancing the field of precision medicine.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Nirvana is an AI-native financial infrastructure shaping the future of Agentic DeFi. - Redefining DeFi with AI Agents – Nirvana builds AI frameworks for DEFAI agents to maximize capital efficiency - AI-Native On-Chain Protocols – Empowering DEFAI agents with AI-native protocols to autonomously launch innovative financial instruments and optimize strategies

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Nucleai Ltd. is a spatial biology company based in Tel Aviv-Yafo, Israel, founded in 2017. It has developed an AI-powered pathology platform that enhances drug development and improves patient outcomes by analyzing tissue datasets to provide insights into cancer biology. The platform is designed to detect various diseases, including cancer, prostate, breast, and gastrointestinal conditions, through advanced machine learning and computer vision techniques. By improving the interpretation of biopsies and supporting treatment decisions, Nucleai aims to increase the efficacy of clinical trials and enhance patient care. The company collaborates with leading pharmaceutical firms, licensing its technology for internal research and participating in biomarker discovery projects. Nucleai serves hospitals and laboratories primarily in the United States and Israel.

SandboxAQ is a company that develops artificial intelligence and quantum technology solutions aimed at addressing complex business and scientific challenges. By integrating expertise from multiple disciplines, including physics, computer science, and mathematics, the company creates Large Quantitative Models and AI sensing applications tailored for various industries. Its offerings are designed to provide practical solutions in sectors such as financial services, healthcare, telecommunications, and cybersecurity. Through its innovative software, SandboxAQ enables clients to tackle significant computational challenges and advance their technological capabilities.

Satellite Bio is a company dedicated to advancing cell therapy and regenerative medicine through innovative approaches in synthetic biology and tissue engineering. It develops proprietary, off-the-shelf implantable satellite organs, which are designed as living therapeutic solutions aimed at addressing complex diseases. By focusing on creating these advanced cell therapies, Satellite Bio seeks to transform the lives of patients suffering from serious health conditions, offering new hope for effective treatment options.

Cohere is a technology company that specializes in natural language processing (NLP) software, designed to enhance the ability of machines to understand human language. By leveraging advanced large language models, Cohere provides developers and businesses with tools that enable them to create applications capable of interpreting meaning, sentiment, and tone from text. This capability not only improves comprehension but also facilitates the development of more personalized user experiences. The company's focus is on making these sophisticated language models safely accessible, ensuring that organizations can harness the power of NLP to better engage with their users and derive insights from vast amounts of textual data.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

Metaphysic is a company specializing in synthetic media creation software that enhances human expression through ethical application. The firm's innovative platform reconstructs low-resolution film and produces natural-looking facial representations, enabling content creators to edit expressions, facial characteristics, or entire faces. By leveraging artificial intelligence, Metaphysic facilitates the production of realistic and immersive content, advancing the possibilities within the metaverse and beyond. The company's technology aims to empower creators by providing tools that expand the frontiers of digital storytelling and expression.

ONI is a pioneering company in super-resolution microscopy, dedicated to making advanced imaging technology accessible to researchers. Its flagship product, the Nanoimager, is the first benchtop-sized super-resolution microscope, significantly enhancing usability and precision in biological research. This innovative device allows users to access various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by leading laboratories worldwide, including institutions such as the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize super-resolution fluorescence imaging, thereby accelerating scientific discovery and aiding in disease research by enabling researchers to visualize and comprehend the intricate details of life at the molecular level. Recognized for its contributions to the field, ONI has received accolades for its innovative approach and commitment to enhancing the effectiveness and accessibility of scientific research.

Nodexus is a biotech startup focused on providing innovative solutions for live single-cell isolation in the industrial, biopharma, clinical research, and academic sectors. The company commercializes the NX One platform, which features a low-cost, low-infrastructure hardware system and single-use disposable microfluidic cartridges. This platform is designed to enhance workflows related to gene editing, cell line and antibody development, and studies on tumor heterogeneity. By offering affordable automated cell isolation, Nodexus aims to accelerate biological research and make advanced technologies more accessible to a wider range of clients.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Verge Genomics is a biotechnology company focused on transforming drug discovery through the application of artificial intelligence. Founded by experts in machine learning and seasoned neuroscience drug developers, the company aims to leverage advancements in computational genomics and insights into neuroscience to discover innovative therapeutics for neurodegenerative diseases. Its drug discovery platform employs machine learning algorithms to analyze large datasets, identifying potential drug targets and predicting effective treatments. By accelerating the development of life-saving therapies, Verge Genomics seeks to enhance patient outcomes and reduce the costs associated with pharmaceutical development, thereby addressing critical challenges in the healthcare sector.

Exai Bio is a next-generation liquid biopsy company that specializes in the early diagnosis of cancer through its proprietary RNA-based platform. This innovative platform focuses on the analysis of cell-free RNA profiles, particularly orphan non-coding RNA and small RNA sequences that are typically absent in normal tissues but prevalent in tumors. By leveraging advanced artificial intelligence and machine learning algorithms, Exai Bio provides clinical insights into cancer biology, enabling healthcare professionals to identify cancer accurately and at its earliest stages. The company's approach not only enhances diagnostic precision but also informs personalized care treatments for patients.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

MedArrive, Inc. is a New York-based company that operates a software-as-a-service health platform designed to enhance care management by connecting healthcare providers with patients in their homes. The platform integrates clinical data into electronic medical records and facilitates communication and billing processes. By utilizing emergency medical services professionals, MedArrive enables healthcare providers to deliver high-quality care at home, improving access for vulnerable populations while reducing overall healthcare costs. This innovative approach fosters patient self-advocacy and continuity of care, helping to re-engage patients in primary care and enhance health outcomes. MedArrive's technology and holistic care model represent a strategic effort to bridge the gap between virtual care and in-person support, ultimately benefiting both patients and healthcare providers.

Mekonos Inc. is a biotechnology company founded in 2017 and based in San Francisco, California, specializing in the design, development, and production of gene and cell therapies. The company has created a proprietary cell-engineering platform that utilizes a silicon chip automated architecture to advance the field of genome editing. This innovative system-on-a-chip technology allows for the precise control of individual nanoneedles to inject single cells in a parallel architecture, enabling the industrial-scale production of engineered therapies for a range of genetic diseases, including cancers. Mekonos aims to provide healthcare providers with a reliable and reusable manufacturing system that can deliver various therapeutic molecules across different primary cell types, thus enhancing drug discovery and development processes.

Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

ScienceIO is a Massachusetts-based company established in 2019 by Gaurav Kaushik and Will Manidis. It specializes in developing a biomedical language platform that transforms unstructured biomedical data into contextualized information. The platform is designed to detect and extract biomedical terms, clinical variables, and medical codes from complex medical texts, thereby linking this information to create actionable insights. By connecting medical concepts, ScienceIO enables users to perform powerful queries and gain easy access to relevant medical data and alternatives, facilitating better decision-making in the biomedical field.

Gretel.ai, founded in 2019 and based in San Diego, California, specializes in developing a multimodal synthetic data platform that utilizes advanced generative AI and privacy-enhancing technologies. The company enables developers to create artificial datasets that mirror the characteristics of real data, facilitating the development and testing of AI models without risking privacy. Gretel's platform incorporates machine learning to categorize data such as names and addresses, providing features like automatic data labeling and power testing. This allows developers to safely and efficiently experiment, collaborate, and innovate with customer data while ensuring compliance with privacy standards.

Wise Systems Inc. is a technology company that specializes in developing autonomous dispatch and routing software aimed at enhancing last-mile delivery operations across various industries, including food and beverage, courier, and field service. Founded in 2014 and based in Cambridge, Massachusetts, the company leverages machine learning to improve fleet efficiency and customer service. Its platform includes tools such as Scheduler for creating optimized route plans, Dispatcher for real-time monitoring of deliveries, and a Customer Portal that provides recipients with accurate ETAs. Wise Systems' software processes millions of data points to make intelligent, real-time decisions, which can lead to significant reductions in mileage and late deliveries. By integrating advanced algorithms, the company enables fleet managers to optimize their operations and reduce costs, ultimately improving the overall delivery experience for customers.

Formation Bio is a biotechnology company dedicated to accelerating drug development and enhancing patient access to new treatments by reimagining clinical trials. The company has developed a platform that scales a network of clinical trial sites integrated within existing medical practices. By utilizing a roaming cohort of certified research coordinators and leveraging advanced software and data analytics, Formation Bio enables researchers to optimize their access to human subjects for various studies, including clinical trials and psychological research. This innovative approach aims to streamline the clinical trial process, ultimately facilitating faster delivery of new therapies to patients.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Cohere is a technology company that specializes in natural language processing (NLP) software, designed to enhance the ability of machines to understand human language. By leveraging advanced large language models, Cohere provides developers and businesses with tools that enable them to create applications capable of interpreting meaning, sentiment, and tone from text. This capability not only improves comprehension but also facilitates the development of more personalized user experiences. The company's focus is on making these sophisticated language models safely accessible, ensuring that organizations can harness the power of NLP to better engage with their users and derive insights from vast amounts of textual data.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

ImmuneID is a precision immunology company that specializes in identifying and therapeutically targeting antibody interactions responsible for immune diseases. Utilizing a proprietary platform, it employs massively parallel, multiplexed, and unbiased systems to analyze millions of these interactions. This innovative approach allows researchers to observe human immune responses throughout the progression of various diseases, including autoimmunity, severe allergies, oncology, and infectious diseases. By focusing on the intricate dynamics of the immune system, ImmuneID aims to develop more effective therapeutics that can improve patient outcomes in these challenging areas of health.

Primer Technologies, Inc., established in 2014 and headquartered in San Francisco, specializes in developing software that leverages machine learning and natural language processing to analyze vast amounts of textual data across multiple languages. Its platform automates the parsing and collation of documents, uncovering insights and generating reports comparable to those produced by human analysts. This enables governments and corporations to better understand and monitor global information, facilitating informed decision-making.

Faro Health is a developer of a cloud-based medical platform that aims to standardize, automate, and streamline the challenges associated with clinical trials. The company's innovative platform utilizes an integrated clinical development environment, which simplifies the design and authoring processes of complex clinical studies. By leveraging advanced digital protocols, Faro Health provides clinical researchers with in-context, intuitive insights throughout the authoring process. This approach allows researchers to optimize their study designs by reducing the administrative burden of clinical protocols, enabling them to concentrate on the critical decisions that enhance clinical value.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

TwinStrand Biosciences, established in 2015 and based in Bellevue, Washington, specializes in advancing DNA sequencing technology. The company's core innovation, Duplex Sequencing, enhances sequencing accuracy by over 10,000 times, enabling the detection of previously invisible mutations. This breakthrough technology has wide-ranging applications, including oncology, infectious disease diagnosis, organ transplant monitoring, genetic health, and forensics.

Current Health Limited is a healthcare technology company based in Edinburgh, United Kingdom, that specializes in wearable devices for monitoring patient vitals. Founded in 2014 and originally known as Snap40 Limited, the company rebranded in December 2018. Current Health's devices are designed to measure critical health indicators such as oxygen saturation, respiration rate, pulse rate, temperature, motion, activity, and posture, enabling early identification of potential health issues. Their patient monitoring platform facilitates the management of patients at home by collecting and analyzing data to detect and predict health deterioration. This allows patients to share daily activities, report symptoms, and complete structured questionnaires, ultimately helping healthcare providers reduce risks and costs associated with patient care.

C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.

Meatable is a Dutch food production company that specializes in creating cultured meat using stem cell technology. Founded in 2019, the company employs pluripotent stem cells to transform various types of cells into muscle or fat tissue, eliminating the need for animal slaughter. This process enables Meatable to produce sustainable, guilt-free meat without compromising taste and texture.

Miroculus, Inc. is a biotechnology company specializing in non-invasive molecular data gathering and analysis solutions. Founded in 2014 and based in San Francisco, California, Miroculus develops advanced digital microfluidic technology that automates and miniaturizes genomic protocols, such as next-generation sequencing library preparation, cell editing, and synthetic biology. The company's hands-off sample-to-answer platform provides assay flexibility and integrates seamlessly into existing workflows, enabling the detection and monitoring of diseases at the molecular level. Miroculus serves a wide range of clients, including academic institutions, genomic research centers, pharmaceuticals, biotechnology firms, and diagnostic companies, offering low-cost, accurate, and minimally invasive molecular testing tools with its proprietary cartridge-based system.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

WithMe Health, LLC is a medication guidance company founded in 2018 and based in San Mateo, California. It offers a personalized medication guidance solution that tailors medication selection to individual needs, guiding members through their medication journey. By replacing traditional pharmacy benefit managers, WithMe Health provides an enhanced range of services that utilize modern technology and extensive datasets. The platform employs artificial intelligence to create customized medication experiences for employees and their families, focusing on proactive, adaptive, and engaging support. With an emphasis on optimizing health outcomes and value, WithMe Health aims to reduce costs for employers while aligning interests across the pharmaceutical value chain.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Neocis, Inc. is a Miami-based company that specializes in the development and manufacturing of robotic guidance systems for dental implant procedures. Founded in 2009, Neocis offers Yomi, a precision robotic instrument that aids in the placement of dental implants by integrating computer imagery from CT scans with the surgical planning process. This technology enhances the capabilities of dental surgeons, providing multi-sensory feedback to improve the accuracy and efficiency of procedures. Yomi is designed to facilitate a minimally invasive approach, allowing for quicker surgeries and faster patient recovery. The company’s focus is on collaborating with dental professionals to address surgical challenges and advance patient care through innovative robotics.

Dialpad, Inc. is a cloud-based communications platform that specializes in enterprise solutions, offering a comprehensive suite of services including voice, video, group messaging, SMS, MMS, conferencing, and sharing of screens and documents. Founded in 2002 and based in San Francisco, the company has transformed its offerings through AI-powered features such as real-time transcription, automated note-taking, live sentiment analysis, and voice analytics. Dialpad's products, which include Dialpad, Dialpad Sell, UberConference, and Dialpad Contact Center, are designed to enhance collaboration and communication for businesses, enabling employees to work securely from any location and device. The company serves notable clients such as Motorola Solutions, ClassPass, Warby Parker, and Vivint, and has strategic partnerships with industry leaders like SoftBank Corp. Dialpad was previously known as Switch Communications, Inc. before rebranding in 2016.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Thrive Earlier Detection Corp. is a healthcare company focused on revolutionizing cancer diagnosis through its innovative blood testing platform. The company specializes in CancerSEEK, a liquid biopsy test that analyzes genomic mutations in tumor DNA and protein markers in plasma to detect various types of cancer at their earliest stages, even before symptoms arise. Founded in 2018 and headquartered in Cambridge, Massachusetts, with an additional office in Baltimore, Maryland, Thrive aims to integrate earlier cancer detection into routine medical care. The company's approach combines targeted DNA and protein analysis with real-world data and machine learning to provide comprehensive result interpretation and facilitate follow-up testing and oncology care. Thrive Earlier Detection Corp. operates as a subsidiary of Exact Sciences Corporation, reflecting its commitment to enhancing cancer detection and improving patient outcomes.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Evidation Health, Inc. is a California-based company that specializes in developing digital tools and technologies for healthcare data analytics. Founded in 2012, the company connects digital health firms with healthcare providers, payers, and other stakeholders through its advanced technology solutions. Its primary offerings include a data platform that transforms everyday behavior data from various sources, such as sensors and devices, into meaningful health insights, and a technology-enabled service called Studies that facilitates real-world research using this data. Evidation Health aims to enhance the understanding of how daily behaviors impact health and disease, ultimately empowering individuals to engage in better health outcomes. The company's commitment to user privacy and control over health data has garnered trust from millions of individuals, enabling them to participate in innovative health programs and research.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Founded in 2017 and originally named Llama Therapeutics, the company aims to address significant unmet medical needs in neuropsychiatry, neurodegeneration, and neuroinflammation. Autobahn's lead candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential adjunctive treatment for multiple sclerosis, adrenomyeloneuropathy, major depressive disorder, and bipolar disorder depression. The company employs a brain-targeting chemistry platform that allows for precise tuning of CNS exposure while pursuing validated clinical and biological targets, guided by biomarkers, to unlock new therapeutic opportunities.

Phaidra, Inc. is a Seattle-based company established in 2019 that specializes in designing and developing artificial intelligence solutions for industrial sectors in the United States. The company focuses on providing AI and machine learning technologies aimed at enhancing performance in large-scale facilities. Phaidra's offerings include a virtual plant operator service that utilizes closed-loop AI control to empower operations teams in mission-critical environments. By analyzing extensive sensor data, Phaidra creates intelligent agents that automatically optimize and manage complex industrial processes. This innovative approach helps clients improve energy efficiency, increase safety and stability, and maximize operational yield, contributing to greater sustainability in their operations.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

Legacy is a company focused on transforming male fertility through innovative testing and preservation solutions. Founded by healthcare and fertility experts, Legacy provides home-based kits that allow men to analyze, improve, and preserve their sperm without the need to visit a clinic. Their offerings include sperm analysis and cryogenic storage options, facilitating the preservation of fertility for clients in a straightforward and accessible manner. The company collaborates with leading hospitals, fertility clinics, and progressive employers to ensure high-quality services. Legacy has garnered recognition through various awards, including victories at TechCrunch Disrupt and MassChallenge Boston, and has attracted investment from notable firms such as Bain Capital Ventures and Section 32.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

XOKind Inc. is an artificial intelligence software company based in San Diego, California, founded in 2019. It specializes in developing AI agents that enhance the travel and leisure experience by learning users' preferences through their calendars, emails, photos, social media, and in-app interactions. The company's innovative platform aims to simplify human planning and decision-making, allowing users to navigate the complexities of travel planning more efficiently. By distilling vast amounts of information, XOKind provides a tailored travel planning experience that caters to individual preferences.

Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company specializes in induced pluripotent stem cells (iPSCs) to create patient-specific cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By combining genomic approaches with stem cell biology, Aspen Neuroscience aims to address significant unmet medical needs and modify the progression of Parkinson's disease through personalized and restorative treatments.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Freenome, Inc. is an artificial intelligence genomics biotech company based in South San Francisco, California, founded in 2014. The company focuses on developing accurate, accessible, and non-invasive blood tests for the early detection of cancer and treatment selection. Utilizing a proprietary multi-omics platform, Freenome employs advanced algorithms to analyze cell-free genomic data, which aids in identifying early-stage cancers and other diseases. This innovative approach aims to transform disease management by enabling timely interventions and proactive treatment strategies. In addition to its diagnostic solutions, Freenome also offers clinical research services to further advance cancer detection and management.

Cradle Genomics, Inc. is a biotechnology company focused on advancing non-invasive prenatal testing (NIPT) through comprehensive fetal genetic analysis and pregnancy health screening solutions. Founded in 2018 and headquartered in San Diego, California, with research and development operations in Detroit, Michigan, the company aims to enhance the knowledge available to expectant parents. Cradle Genomics specializes in analyzing fetal cells collected during the first trimester, allowing for rapid and safe testing that poses no risk to the mother or developing fetus. By providing critical insights early in pregnancy, Cradle Genomics empowers women to make informed health decisions.